bivalent pfizer bnt vaccine (Pfizer Inc)
86
Structured Review
Pfizer Inc
bivalent pfizer bnt vaccine
Bivalent Pfizer Bnt Vaccine, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bivalent+pfizer+bnt+vaccine/bivalent+bnt+pfizer+vaccine/pmc12390948__mmc5-912-44-45
Average 86 stars, based on 1 article reviews
Bivalent Pfizer Bnt Vaccine, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bivalent+pfizer+bnt+vaccine/bivalent+bnt+pfizer+vaccine/pmc12390948__mmc5-912-44-45
Average 86 stars, based on 1 article reviews
bivalent pfizer bnt vaccine - by Bioz Stars,
2026-10
86/100 stars
Images
Related Articles
Immunopeptidomics:Article Title: Immunogenicity and safety of ‘Comvigen’, a bivalent SARS-CoV-2 vaccine, in comparison to Comirnaty bivalent vaccine in Thailand: a phase 2, non-inferiority randomised trial Article Snippet: .. Sample size calculation for primary immunogenicity objective The sample size calculation is based on these hypothesis testings of immunobridging analysis determined by the results of pseudovirus neutralizing antibody titer (pSVNT-50) against wildtype virus at 4 weeks after the booster dose of COMVIGEN vaccine or Article Title: Immunogenicity and safety of ‘Comvigen’, a bivalent SARS-CoV-2 vaccine, in comparison to Comirnaty bivalent vaccine in Thailand: a phase 2, non-inferiority randomised trial Article Snippet: .. 8.1 Sample Size Calculation Sample size calculation for primary immunogenicity objective: Version 1.0; 17SEP2024 CONFIDENTIAL Page 62 of 231 The sample size calculation is based on these hypothesis testings of immunobridging analysis determined by the results of pseudovirus neutralizing antibody titer (pSVNT-50) against wild-type virus at 4 weeks after the booster dose of COMVIGEN vaccine or Virus:Article Title: Immunogenicity and safety of ‘Comvigen’, a bivalent SARS-CoV-2 vaccine, in comparison to Comirnaty bivalent vaccine in Thailand: a phase 2, non-inferiority randomised trial Article Snippet: .. Sample size calculation for primary immunogenicity objective The sample size calculation is based on these hypothesis testings of immunobridging analysis determined by the results of pseudovirus neutralizing antibody titer (pSVNT-50) against wildtype virus at 4 weeks after the booster dose of COMVIGEN vaccine or Article Title: Immunogenicity and safety of ‘Comvigen’, a bivalent SARS-CoV-2 vaccine, in comparison to Comirnaty bivalent vaccine in Thailand: a phase 2, non-inferiority randomised trial Article Snippet: .. 8.1 Sample Size Calculation Sample size calculation for primary immunogenicity objective: Version 1.0; 17SEP2024 CONFIDENTIAL Page 62 of 231 The sample size calculation is based on these hypothesis testings of immunobridging analysis determined by the results of pseudovirus neutralizing antibody titer (pSVNT-50) against wild-type virus at 4 weeks after the booster dose of COMVIGEN vaccine or |